Skip to main content
AAN.com
Brief Communications
August 7, 2006

Anti-MuSK antibodies: Correlation with myasthenia gravis severity

August 8, 2006 issue
67 (3) 505-507

Abstract

The authors measured anti–muscle-specific tyrosine kinase (anti-MuSK) antibodies (Abs) in 83 serum samples from 40 patients and evaluated their correlation with myasthenia gravis severity and treatment response. Ab concentrations were often reduced by immunosuppression but not after thymectomy. Both in individual cases and in the whole population, a correlation between Ab levels and disease severity was found.

Get full access to this article

View all available purchase options and get full access to this article.

Supplementary Material

File (e1.jpg)

References

1.
Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med 2001;7:365–368.
2.
Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis. Brain 2003;126:2304–2311.
3.
Selcen D, Fukuda T, Shen XM, Engel AG. Are MuSK antibodies the primary cause of myasthenic symptoms? Neurology 2004;62:1945–1950.
4.
Shiraishi H, Motomura M, Yoshimura T, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis. Ann Neurol 2005;57:289-293.
5.
Jaretzki A 3rd, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis. Recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 2000;55:16-23.
6.
Lindstrom JM, Seybold ME, Lennon VA, Wittingham S, Duane DD. Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value. Neurology 1976;26:1054–1059.
7.
Vincent A, Leite MI. Neuromuscular junction autoimmune disease: muscle specific kinase antibodies and treatments for myasthenia gravis. Curr Opin Neurol 2005;18:519–525.
8.
Kong XC, Barzaghi P, Ruegg MA. Inhibition of synapse assembly in mammalian muscle in vivo by RNA interference. EMBO Rep 2004;5:183–188.
9.
Lindstrom J. Is “seronegative” MG explained by autoantibodies to MuSK? Neurology 2004;62:1920–1921.
10.
Lauriola L, Ranelletti F, Maggiano N, et al. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis. Neurology 2005;64:536–538.

Information & Authors

Information

Published In

Neurology®
Volume 67Number 3August 8, 2006
Pages: 505-507
PubMed: 16894117

Publication History

Published online: August 7, 2006
Published in print: August 8, 2006

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

E. Bartoccioni, PhD
From the Departments of General Pathology (E.B., F.S., M.M.) and Neurosciences (A.E., F.C., G.M.M.), Catholic University, Rome, Italy.
F. Scuderi, PhD
From the Departments of General Pathology (E.B., F.S., M.M.) and Neurosciences (A.E., F.C., G.M.M.), Catholic University, Rome, Italy.
G. M. Minicuci, MD
From the Departments of General Pathology (E.B., F.S., M.M.) and Neurosciences (A.E., F.C., G.M.M.), Catholic University, Rome, Italy.
M. Marino, PhD
From the Departments of General Pathology (E.B., F.S., M.M.) and Neurosciences (A.E., F.C., G.M.M.), Catholic University, Rome, Italy.
F. Ciaraffa, MD
From the Departments of General Pathology (E.B., F.S., M.M.) and Neurosciences (A.E., F.C., G.M.M.), Catholic University, Rome, Italy.
A. Evoli, MD
From the Departments of General Pathology (E.B., F.S., M.M.) and Neurosciences (A.E., F.C., G.M.M.), Catholic University, Rome, Italy.

Notes

Address correspondence and reprint requests to Dr. A. Evoli, Neuroscience Department, Catholic University, L.go F. Vito,1-00168 Roma, Italy; e-mail: [email protected]

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Steroid pulse therapy was effective against anti–muscle-specific kinase antibody–positive myasthenia gravis crisis: a case reportステロイドパルスが奏効したクリーゼ発症抗MuSK抗体陽性重症筋無力症の1例, Rinsho Shinkeigaku, 63, 6, (379-381), (2023).https://doi.org/10.5692/clinicalneurol.cn-001832
    Crossref
  2. Current Biomarker Strategies in Autoimmune Neuromuscular Diseases, Cells, 12, 20, (2456), (2023).https://doi.org/10.3390/cells12202456
    Crossref
  3. Conventional and emerging treatments and controversies in myasthenia gravis, Expert Review of Neurotherapeutics, 23, 5, (445-456), (2023).https://doi.org/10.1080/14737175.2023.2207739
    Crossref
  4. Disease-Based Prognostication: Myasthenia Gravis, Seminars in Neurology, 43, 05, (799-806), (2023).https://doi.org/10.1055/s-0043-1775791
    Crossref
  5. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells, Nature Biotechnology, 41, 9, (1229-1238), (2023).https://doi.org/10.1038/s41587-022-01637-z
    Crossref
  6. Treatment of acquired autoimmune myasthenia gravis: Where are we today?, Galenika Medical Journal, 1, 2, (44-51), (2022).https://doi.org/10.5937/Galmed2202044L
    Crossref
  7. Corticosteroid Treatment-Resistance in Myasthenia Gravis, Frontiers in Neurology, 13, (2022).https://doi.org/10.3389/fneur.2022.886625
    Crossref
  8. Long-Term Efficacy of Non-steroid Immunosuppressive Agents in Anti-Muscle-Specific Kinase Positive Myasthenia Gravis Patients: A Prospective Study, Frontiers in Neurology, 13, (2022).https://doi.org/10.3389/fneur.2022.877895
    Crossref
  9. Role of autoantibody levels as biomarkers in the management of patients with myasthenia gravis: A systematic review and expert appraisal, European Journal of Neurology, 30, 1, (266-282), (2022).https://doi.org/10.1111/ene.15565
    Crossref
  10. Utilidad de los anticuerpos en las enfermedades de la unión neuromuscular: revisión, Neurología Argentina, 14, 1, (37-50), (2022).https://doi.org/10.1016/j.neuarg.2021.08.004
    Crossref
  11. See more
Loading...

View Options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

View options

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share